Elicio Therapeutics Reports Inducement Grants

BOSTON, June 18, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio Therapeutics" or "Elicio")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the

GlobeNewswireJun 18 08:30 ET

Express News | Elicio Therapeutics Inc - Sales Agreement Prospectus Covering Offering of up to $40 Mln of Common Stock That May Be Issued and Sold From Time to Time

ReutersJun 3 17:26 ET

Express News | Elicio Therapeutics Inc Files for Mixed Shelf of up to $200 Mln – SEC Filing

ReutersJun 3 17:25 ET

Elicio Therapeutics On May 23 Announced Preliminary Data From Ongoing AMPLIFY-7P Phase 1a Study Of ELI-002 7P In Patients With MKRAS-Driven Solid Tumors At 2024 ASCO Annual Meeting

ELI-002 7P administered as a monotherapy was well tolerated and able to generate a ~100x mKRAS-specific expanded T cell response relative to baseline levelsELI-002 7P generated an mKRAS-specific T cel

BenzingaMay 24 12:56 ET

Express News | Elicio Therapeutics: Eli-002 7P Was Well Tolerated With T Cell Responses Correlating With a Reduction in Tumor Biomarkers at Recommended Phase 2 Dose

ReutersMay 23 17:32 ET

Express News | Elicio Therapeutics Inc: Eli-002 7P Administered as a Monotherapy Was Well Tolerated

ReutersMay 23 17:31 ET